静脉血栓栓塞的化学预防在整形外科:一个随机对照试验的apixaban对Enoxaparin
Arash Momeni1, Pooja S Yesantharao1, Shannon Meyer1
1Division of Plastic & Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Plastic and reconstructive surgery
|May 6, 2025
概括
阿皮克萨班提供了一个安全的,固定剂量的口服替代品,以防止自主乳房重建后静脉血栓塞栓症 (VTE). 这项研究发现这两种药物之间的出血或VTE事件没有显著差异.
科学领域:
- 整形外科 整形外科 整形外科
- 血管外科 血管外科
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉血栓塞栓症 (VTE) 是一个显著的手术风险,目前的预防措施,如埃诺沙巴林具有局限性.
- 埃诺沙巴林的限制包括基于体重的剂量,XA因子监测和皮下注射,可能导致突破性VTE.
- 有限的文献存在于VTE化学预防的整形外科手术中直接的XA抑制剂,如apixaban.
研究的目的:
- 为了比较apixaban与enoxaparin在VTE化疗预防中的安全性和有效性.
- 评估阿皮克萨班作为高风险乳腺癌患者接受自主乳腺重建的埃诺沙巴林的潜在替代品.
- 在接受阿皮克萨班或埃诺沙巴林的患者中调查出血事件和症状性VTE的发生率.
主要方法:
- 进行了一项单中心,盲目,随机对照试验.
- 这项研究比较了以诺沙巴林和阿皮克萨班用于VTE化疗预防在接受微手术乳房重建的妇女与自由腹.
- 79名患者被录取并随机分配给埃诺沙巴林 (n=40) 或阿皮克萨班 (n=39).
主要成果:
- 埃诺沙巴林和阿皮克萨班组之间的人口统计和并发病情况相似.
- 一次出血事件 (3%) 发生在阿皮克萨班手臂,一个 (3%) 发生在埃诺沙巴林手臂.
- 在任何治疗臂中都没有报告任何症状性VTE事件,在阿皮克萨班和埃诺沙巴林之间,出血事件的调整几率相似.
结论:
- 在这种患者群体中,阿皮克萨班在VTE化疗预防中表现出与埃诺沙巴林相似的安全性.
- 艾皮克萨班是一种安全的,固定剂量,口服选择,用于自主乳房重建后的静脉瘤预防.
- 这些发现表明,在重建外科手术中,对口服药物进行VTE预防的潜在范式转变.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
532
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
532
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
986
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
986
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
97
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
97


